Table 2.
Characteristics of patients with haemoglobinopathies and chronic hepatitis C before starting treatment with direct acting antivirals (n=11).
| Age (years) | 40 (33–59) |
|
| |
| Male/Female | 7/4 |
|
| |
| β-thalassemia major | 10 |
| Sickle cell anaemia/β-thalassemia | 1 |
|
| |
| AST (IU/L) | 51 ± 43 |
| ALT (IU/L) | 41 ± 33 |
| γ-GT ( IU/L) | 34 ± 21 |
| ALP (IU/L) | 76 ± 15 |
| Albumin (g/dl) | 4.2 ± 0.5 |
| Bilirubin (mg/dl) | 1.4 ± 2.1 |
| PLT (×103/μl) | 374 ± 132 |
| Ferritin (ng/ml) | 1331 (82–6222) |
|
| |
| HCV-RNA (IU/ml) | 3.9 ×106 (1.5 ×106–9.85 ×106) IU/ml |
|
| |
| Genotypes | |
| 1a/ 1b/ 2/ 3/4 | 2/ 4/ 1/ 3/1 |
|
| |
| Cirrhosis (%) | 6 (54.5%) |
|
| |
| Elastography (kPa) | 15.5 (9.2–34.3) |
| F0–F1 | 0 |
| F1–F2 | 1 |
| F2–F3 | 3 |
| F3–F4 | 7 |
|
| |
| MRI T2* (msec) (n=7) | 13.2 (3.6–31) |
Abbreviations are same as in text.